The Shanghai Stock Exchange terminated the listing review of Huihe Medical Science and Technology Innovation Board. Regarding the Shanghai Stock Exchange's termination of Huihe Medical's financing valuation, the market may reassess relevant expectations. Changes in financing and valuation will affect the market’s judgment on technology narratives and funding preferences. Do you think we should pay more attention to the implementation changes or the funding response in the future?